A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2020-04-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether nivolumab monotherapy or in combination
with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR)
without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.